Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis

ABSTRACT Background Blinding mitigates bias in randomized trials and may be especially crucial for surrogate endpoints, such as progression‐free survival (PFS). Here, we characterize utilization of and factors associated with blinding in Phase III oncology trials with PFS primary endpoints. Methods...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Gabrielle Brown, Pavlos Msaouel, Avital M. Miller, Ramez Kouzy, Timothy A. Lin, Joseph Abi Jaoude, Ethan B. Ludmir, Alexander D. Sherry
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-08-01
Colecção:	Cancer Medicine
Assuntos:	bias blinded independent central review double‐blind oncology Phase III randomized trials
Acesso em linha:	https://doi.org/10.1002/cam4.71097
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!